Big Data Genome Marketing 
pharmaphorum
DECEMBER 8, 2022
The advent of biologic therapies in the 1970s along with the decoding of the human genome in 2003 heralded an explosion in pharmaceutical innovation. This has led to an increase in products coming to market with single‑arm Phase 3 data and surrogate endpoints or Phase 2b data, with planned confirmatory data to be released in the future.
Pharma Marketing Network
OCTOBER 14, 2024
As the landscape evolves, pharma executives must adapt their marketing strategies to remain competitive and effectively reach their target audiences. The rise of big data analytics, artificial intelligence, and machine learning has revolutionized drug discovery, development, and marketing.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
OCTOBER 17, 2024
As we approach 2025, the pharmaceutical industry is witnessing a seismic shift in marketing strategies, driven by technological advancements and evolving consumer expectations. This article explores the top pharma marketing trends that are set to redefine the landscape in the coming years.
pharmaphorum
APRIL 8, 2022
Her research area is the secondary use of observational data of patients with rare and unclear diseases; with attention to the research data infrastructure and terminologies. In 2021, she co-founded OHDSI Germany, which is as a national node of the Observational Health Data Sciences and Informatics (OHDSI) Europe. .
pharmaphorum
DECEMBER 14, 2020
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. The post 5th Microbiome Movement – Drug Development Summit Europe 2021 appeared first on.
pharmaphorum
JULY 4, 2022
And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar.
pharmaphorum
SEPTEMBER 18, 2020
German and Swiss pharma companies dominated the Swedish market at this time and it wasn’t until 1913 that the discussions were turned into a pharmaceutical company, Astra AB. Astra introduced two important product families onto the Swedish market in 1948: penicillin and anaesthetics, initially in the form of Xylocaine.
Expert insights. Personalized for you.
96 
Let's personalize your content